<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00276926</url>
  </required_header>
  <id_info>
    <org_study_id>HES0203</org_study_id>
    <nct_id>NCT00276926</nct_id>
  </id_info>
  <brief_title>Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias</brief_title>
  <official_title>Open Label Pilot Phase II Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bologna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Bologna</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the clinical anti-proliferative activity of STI571
      (Glivec®, Novartis, Pharma) in patients with HES defined as:

        1. Idiopathic Hypereosinophilic Syndrome (secondary HES), defined as a peripheral blood
           eosinophilia greater than 1,500 cells/µL for longer than 6 months, absence of other
           apparent aetiologies for eosinophilia and with or without signs and symptoms of organ
           involvement, irrespective to expression of any of imatinib targets (c-Kit receptor,
           PDGFR, bcr-abl receptor) on bone marrow cells.

        2. Familiar hypereosinophilia defined as a peripheral blood eosinophilia greater than 1,500
           cells/µL for longer than 6 months, absence of other apparent aetiologies for
           eosinophilia and signs and symptoms of organ involvement, irrespective to expression of
           any of imatinib targets (c-Kit receptor, PDGFR, bcr-abl receptor) on bone marrow cells,
           and with a recognized or reported cases of hypereosinophilia in the patient's family.

        3. Chronic myeloproliferative disorder, defined as chronic eosinophilic leukemia (CEL) with
           the presence of blasts (&gt;10%) in the bone marrow (BM), or the presence of immature
           eosinophils in different tissues, or an aggressive clinical course or the presence of
           clonal cytogenetic anomalies.

        4. Myeloproliferative disorder (MPD) with eosinophilia, eosinophilic leukemia or chronic
           myelomonocytic leukemia [myeloproliferative disorders/myelodysplastic syndromes
           (MPD/MDS)] with evidence of:

             -  t(5;12)(q33;p13) by cytogenetic or fluorescent in situ hybridization (FISH)
                analysis, or

             -  ETV6/TEL-PDGFRB fusion transcript by reverse transcription polymerase chain
                reaction (RT-PCR), or

             -  PDGFRB disruption, assessed or suspected, by other translocations with additional
                partner genes (H4, HIP1, CEV14 and Rab5) 5, or

             -  MPD/MDS who have constitutive activation of the gene for platelet-derived growth
                factor receptor beta (PDGFRB) 6 by point mutations
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2003</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of complete response (CR) in all patients at 3rd month</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (CR)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 12th month</measure>
  </secondary_outcome>
  <condition>Hypereosinophilic Syndrome</condition>
  <condition>Chronic Eosinophilic Leukemia (CEL)</condition>
  <condition>Myeloproliferative Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STI571</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Presence of primary or secondary HES

          2. Not a candidate for allogeneic bone marrow transplantation.

          3. ECOG performance score of 0, 1, 2 or 3 (Karnofsky performance score &gt; 40%).

          4. Life expectancy &gt; 4 weeks.

          5. Adequate hepatic and renal function, as defined by serum transaminases &lt; 2.5x upper
             limits of normal (ULN), bilirubin &lt; 1.5x ULN, and creatinine &lt; 1.5x ULN.

          6. Age 18 years or greater.

          7. Post-menopausal, surgically sterile, or taking effective contraception in female
             patients.

          8. Documentation of written informed consent to participate in the trial.

          9. Willingness and ability to comply with scheduled visits, treatment plan, laboratory
             tests, and other study procedures.

        Exclusion Criteria:

        The presence of any of the following will exclude a subject from study enrollment:

          1. Patients with clear evidence of secondary hypereosinophilia.

          2. Acute myeloblastic leukemia with inv(16) positive blast or

          3. CBFb-MYH11 transcripts positive leukemia

          4. Lack of recovery from the acute toxic effects of previous chemotherapy [to common
             toxicity criteria (CTC) grade &gt; 1] with the exception of chemotherapy-induced
             alopecia.

          5. Treatment with any investigational agent within 4 weeks prior to study therapy.

          6. Major surgeries within 4 weeks from study start or not fully recovered from any
             previous surgical procedure.

          7. Presence of any medical or psychiatric condition which may limit full compliance with
             the study or increase the risk associated with study participation or study drug
             administration, including but not limited to

          8. Presence of central nervous system (CNS) illness and involvement of disease.

          9. Active uncontrolled bacterial infection.

         10. Known human immunodeficiency virus (HIV) infection.

         11. Grade 3 or 4 bleeding.

         12. Significant cardiovascular disease (i.e., uncontrolled arrhythmias, unstable angina),
             or a major thromboembolic event (myocardial infarction, stroke, transient ischemic
             attack, pulmonary embolism, or non-catheter-related deep-vein thrombosis) in the last
             6 months. Due to the low cardiac toxicity profile of Glivec, it is not considered an
             exclusion criterion if the presence of severe complications to the viscera, among
             which cardiopathies, and in particular endomyocardial fibrosis, is due or considered
             to be due to HES.

         13. Increased blood eosinophil counts due to the presence of physician-diagnosed asthma.
             However, due to low pulmonary toxicity profile of Glivec, it is not considered an
             exclusion criterion, if HES is associated with asthma, and the presence of severe
             complications damaging the lungs, are considered due to HES.

         14. Pregnancy or breast-feeding.

         15. Malabsorption syndromes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Baccarani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto di Ematologia e Oncologia Medica &quot;L. e A. Seràgnoli&quot; Università degli Studi di Bologna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giovanni Martinelli, MD</last_name>
    <phone>+39 051 6363829</phone>
    <email>gmartino@alma.unibo.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Livia Galletti, PhD</last_name>
    <phone>+39 051 6363829</phone>
    <email>acute@med.unibo.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istituto di Ematologia e Oncologia Medica &quot;L. e A. Seràgnoli&quot; Università degli Studi di Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Giovanni Martinelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michela Rondoni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pier Paolo Piccaluga, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefania Paolini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Medicina Interna - Università di Genova</name>
      <address>
        <city>Genova</city>
        <zip>16100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Gobbi, MD</last_name>
      <phone>+39 010 3532395</phone>
      <email>gobbi@unige.it</email>
    </contact>
    <investigator>
      <last_name>Marco Gobbi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Biochimica e Biotecnologie Mediche - Università degli Studi di Napoli &quot;Federico II&quot;</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrizio Pane, MD</last_name>
      <phone>+ 39 081 7463135</phone>
      <email>fabpane@unina.it</email>
    </contact>
    <investigator>
      <last_name>Fabrizio Pane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia - Università degli Studi di Napoli &quot;Federico II&quot;</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucio Catalano, MD</last_name>
      <phone>+ 39 081 7462068</phone>
      <email>lcatalan@unina.it</email>
    </contact>
    <investigator>
      <last_name>Bruno Rotoli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucio Catalano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C. Medicina Interna II ed Ematologia - Laboratorio di Medicina Interna e Molecolare - A.O. San Luigi</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emanuela Messa, MD</last_name>
      <phone>+39 0119026721</phone>
      <email>emanuelamessa@yahoo.it</email>
    </contact>
    <contact_backup>
      <last_name>Daniela Cilloni, MD</last_name>
      <phone>+39 0119026610</phone>
      <email>daniela.cilloni@unito.it</email>
    </contact_backup>
    <investigator>
      <last_name>Giuseppe Saglio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emanuela Messa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniela Cilloni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia - IRCCS Policlinico S. Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serena Merante, MD</last_name>
      <phone>+39 0382502250</phone>
      <email>s.merante@smatteo.pv.it</email>
    </contact>
    <investigator>
      <last_name>Mario Lazzarino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Serena Merante, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia - Dipartimento di Oncologia ed Ematologia, Presidio Ospedaliero di Ravenna</name>
      <address>
        <city>Ravenna</city>
        <zip>48100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eliana Zuffa, MD</last_name>
      <phone>+39 0544285752</phone>
      <email>e.zuffa@ausl.ra.it</email>
    </contact>
    <investigator>
      <last_name>Alfonso Zaccaria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eliana Zuffa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia - Arcispedale Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Avanzini, MD</last_name>
      <phone>+39 0522296681</phone>
      <email>paolo.avanzini@asmn.re.it</email>
    </contact>
    <investigator>
      <last_name>Luigi Gugliotta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paolo Avanzini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cattedra di Ematologia - Università &quot;Tor Vergata&quot;</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Buccisano, MD</last_name>
      <phone>+39 06 20902674</phone>
      <email>francesco.buccisano@uniroma2.it</email>
    </contact>
    <investigator>
      <last_name>Sergio Amadori, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesco Buccisano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cattedra di Ematologia - Università &quot;La Sapienza&quot;</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuliana Alimena, MD</last_name>
      <phone>+39 06857951</phone>
      <email>alimena@bce.med.uniroma1.it</email>
    </contact>
    <investigator>
      <last_name>Franco Mandelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giuliana Alimena, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia - Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pellegrino Musto, MD</last_name>
      <phone>+39 0882410539</phone>
      <email>p.musto@tin.it</email>
    </contact>
    <investigator>
      <last_name>Angelo Michele Carella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pellegrino Musto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia e Trapianti - Policlinico &quot;Le Scotte&quot;</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Bocchia, MD</last_name>
      <phone>+39 0577586798</phone>
      <email>bocchia@unisi.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Lauria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Monica Bocchia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Medicina II Divisione - Ospedale Santa Chiara</name>
      <address>
        <city>Trento</city>
        <zip>38100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Vivaldi, MD</last_name>
      <phone>+39 0461903307</phone>
      <email>paolo.vivaldi@tn.it</email>
    </contact>
    <investigator>
      <last_name>Mauro Pedrazzoli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paolo Vivaldi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvia Cerù, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Guella, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica - Policlinico Universitario</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Tiribelli, MD</last_name>
      <phone>+39 0432559662</phone>
      <email>mtiribelli@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Renato Fanin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mario Tiribelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2006</study_first_submitted>
  <study_first_submitted_qc>January 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2006</study_first_posted>
  <last_update_submitted>September 14, 2009</last_update_submitted>
  <last_update_submitted_qc>September 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2009</last_update_posted>
  <keyword>Hypereosinophilic Syndrome</keyword>
  <keyword>Eosinophilic leukemias</keyword>
  <keyword>STI571 (Gleevec)</keyword>
  <keyword>PDGF receptor alpha</keyword>
  <keyword>Familiar hypereosinophilia</keyword>
  <keyword>Myeloproliferative disorder (MPD) with eosinophilia</keyword>
  <keyword>myeloproliferative disorders/myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Hypereosinophilic Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

